Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Eddingpharm gets rights to Immutep's ImmuFact IMP321

17 May 2021

Executive Summary

Specialty pharmaceuticals company Eddingpharm International Holdings Ltd. licensed exclusive rights to develop, manufacture, and sell oncology firm Immutep SA’s ImmuFact IMP321 in China, Hong Kong, Macau, and Taiwan.

 

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By